The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
Health Affairs' Senior Deputy Editor Rob Lott interviews Paige Nong of the University of Minnesota about her recent paper that evaluates and explores the current use of artificial intelligence and ...
This article is the first in a new Health Affairs Forefront featured topic, “Health Policy at a Crossroads.” Articles in this topic will offer timely analysis of prominent regulatory ...
President Trump reinstated an expanded version of the so-called “Mexico City policy,” which prevents organizations that receive federal global health funding from providing access to abortion-related ...